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Background: Th2 immune responses are linked primarily to mild and moderate asthma, while Th17 cells,
Interleukin-17A (IL-17) and neutrophilia have been implicated in more severe forms of disease. How Th2-dependent
allergic reactions are influenced by Th17 and IL-17-γδ T cells is poorly understood. In murine models, under some
conditions, IL-17 promotes Th2-biased airway inflammatory responses. However, IL-17-γδ T cells have been
implicated in the inhibition and resolution of allergic airway inflammation and hyperresponsiveness (AHR).
Methods: We compared airway responses in Balb/c mice sensitized to OVA with (and without) a Th2-skewing
aluminum-based adjuvant and the IL-17 skewing, complete Freund’s adjuvant (CFA). AHR was measured invasively
by flexiVent, while serum OVA-IgE was quantified by an enzyme immunoassay. Airway inflammatory and cytokine
profiles, and cellular sources of IL-17 were assessed from bronchoalveolar lavage and/or lungs. The role of γδ T
cells in these responses was addressed in OVA/CFA sensitized mice using a γδ T cell antibody.
Results: Following OVA challenge, all mice exhibited mixed eosinophilic/neutrophilic airway inflammatory profiles
and elevated serum OVA-IgE. Whereas OVA/alum sensitized mice had moderate inflammation and AHR, OVA/CFA
sensitized mice had significantly greater inflammation but lacked AHR. This correlated with a shift in IL-17 production
from CD4+ to γδ T cells. Additionally, OVA/CFA sensitized mice, given a γδ TCR stimulatory antibody, showed increased
frequencies of IL-17-γδ T cells and diminished airway reactivity and eosinophilia.
Conclusions: Thus, the conditions of antigen sensitization influence the profile of cells that produce IL-17, the balance
of which may then modulate the airway inflammatory responses, including AHR. The possibility for IL-17-γδ T cells to
reduce AHR and robust eosinophilic inflammation provides evidence that therapeutic approaches focused on stimulating
and increasing airway IL-17-γδ T cells may be an effective alternative in treating steroid resistant, severe asthma.
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Asthma is a complex disease characterized by airway
inflammation, hyperresponsiveness (AHR) and variable
airflow obstruction [1,2] mediated, at least in part, by an
aberrant T helper (Th)2 [2-4] and/or Th17 response [5-7].
Th2 cells and the associated cytokines, interleukin (IL)-4,
IL-5 and IL-13, are increased in the bronchoalveolar lav-
age (BAL), sputum and bronchial biopsies of asthmatics
and are linked to airway eosinophilia, IgE and reduced
lung function [3,4,8,9]. Th17 cells and their prime effector* Correspondence: elizabeth.fixman@mcgill.ca
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unless otherwise stated.cytokine, IL-17A (hereafter referred to as IL-17), have
more recently been implicated in asthma pathogenesis.
IL-17 expressing cells are increased in the BAL, sputum,
bronchial biopsies and in peripheral blood of asthmatics
[5-7] and are correlated with neutrophilic airway inflam-
mation and resistance to corticosteroid treatment in mod-
erate-to-severe asthmatics [10-12]. Although much of the
human data is approached from either the Th2 or Th17
perspective, they are unlikely to be mutually exclusive.
Asthmatics have been reported to have increases in both
Th2- and Th17-related cytokines [13,14] and Cosmi et al.
have reported increases in a unique subset of CD4+ T cells
expressing both IL-4 and IL-17 [15]. Asthmatics can alsoLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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inflammatory profile [16,17], which may reflect a mixed
immune response.
Eosinophilic airway inflammation, AHR and mucus
production are features of asthma that have been suc-
cessfully modeled in Th2-driven experimental asthma in
the mouse [18,19]. A widely used method of antigen
sensitization involves intraperitoneal (IP) injection(s) of
ovalbumin (OVA) adsorbed to an aluminum-based adju-
vant (hereafter referred to as alum), a potent inducer of
the Th2 response [20]. Comparatively, animal studies of
IL-17 show an important role for Th17 cells on airway
neutrophilia and steroid resistance [21,22]. Intranasal
instillations, as well as epicutaneous routes of OVA sen-
sitization, have been shown to induce a more robust
IL-17 response compared to IP injections of OVA/alum
[23,24]. Furthermore, complete Freund’s adjuvant (CFA), a
strong inducer of IL-17 typically used in experimental
autoimmune encephalomyelitis models, has seen limited
use as an IL-17-skewing adjuvant in murine models of
allergic asthma [22,25].
The Th2/IL-17 relationship has been assessed in differ-
ent Th2-driven models of experimental asthma. A grow-
ing body of evidence suggests that IL-17, when sourced
from Th17 cells, enhances Th2-induced eosinophilic in-
flammation and AHR [24,26], whereas we and others have
shown that IL-17-γδ T cells negatively regulate these re-
sponses [27,28]. We have now compared how two widely
used adjuvants, alum and CFA, modulate OVA-induced
allergic airways disease. Our primary goals were to induce
a mixed Th2/IL-17 inflammatory response and to identify
the cellular source(s) of IL-17. Following airway OVA
challenge, OVA/alum and OVA/CFA sensitized mice
exhibited antigen-induced airway eosinophilia and had
similar total IL-17+ and Th17 BAL fluid cell numbers.
However, the influx of inflammatory cells into the lung, as
well as serum OVA-IgE levels, and BAL fluid IL-17-γδ T
cells were all significantly enhanced in OVA/CFA over
OVA/alum sensitized mice following OVA challenge.
Nevertheless, AHR was completely absent in these highly
inflamed animals, which corresponded to a shift in IL-17
production from CD4+ to γδ T cells. Our secondary goal
was to define the role of IL-17-γδ T cells on AHR and
inflammation. In mice treated with a γδ TCR stimulatory
antibody, the frequency of IL-17-γδ T cells in OVA/CFA
sensitized mice was increased. Consistent with a negative
regulatory role for these cells, AHR and eosinophilia were
both significantly decreased in these mice. Overall, our
data demonstrate that the conditions of initial antigen
sensitization direct production of IL-17 from different po-
pulations of cells, which in turn, may have the ability
to modulate Th2-biased airway inflammatory responses.
These data also suggest that specific enhancement of
IL-17-γδ T cells could inhibit allergic airways responses.Methods
Animals
Wild type Balb/c mice originating from Charles River
Laboratories (Montreal, QC, Canada) were bred and used
at ages 6–10 weeks at the Meakins-Christie Laboratories
Animal Facility. Animal studies were approved by the
McGill University Animal Care Committee and per-
formed following the Canadian Council on Animal Care
guidelines.
Sensitization & airway challenge
Mice were sensitized intraperitoneally (IP) with 100 μg
OVA (Sigma-Aldrich, St. Louis, Missouri, USA) in sterile
PBS with either a 10% solution of Imject Alum (Thermo
Scientific, Rockford, Illinois, USA), a 50% emulsion of
Complete Freund’s Adjuvant (Sigma-Aldrich) or without
adjuvant on days 0 & 7. Each OVA group had a respective
control group injected without OVA. All mice were lightly
anaesthetized with isoflurane and challenged intranasally
(IN) with 30 μl of PBS containing 50 μg of OVA on days
28, 29 & 30 and sacrificed 24 hours after the last airway
challenge.
γδ TCR antibody treatment
Balb/c mice were OVA/CFA sensitized and OVA chal-
lenged according to the protocol above, with the following
exceptions: mice were alternatively challenged on days 42,
43 & 44 and received a total of two 80 μg IV injections of
the UC7-13D5 γδ TCR antibody or Armenian hamster
isotype control antibody (Biolegend, San Diego, California,
US) 2 days and 6 hours before the first airway challenge.
Flow cytometry analysis of BAL fluid and lung cells con-
firmed an increase in the frequency of IL-17-γδ T cells in
mice receiving the γδ TCR stimulatory antibody.
Analysis of airway hyperresponsiveness & airway
inflammation
The AHR readouts, resistance and elastance, were taken
from mice anaesthetized with a cocktail of xylaxine and
sodium pentobarbital, followed by an injection of the
paralyzing agent, pancuronium bromide. Measurements
were determined using the flexiVent small animal ven-
tilator (SCIREQ, Montreal, Quebec, Canada) by exposing
mice to increasing concentrations of aerosolized metha-
choline. Following assessment of AHR, BAL was perfor-
med. Cells, recovered from two-1 ml PBS lavages of the
airways, were pooled and red blood cells lysed before
counting total cells. A portion of the cells was centrifuged
onto glass slides and stained using Diff-Quick (Fisher
Scientific, Ottawa, Ontario, Canada) from which a differ-
ential cell count, based on a 300 cell count from five to
ten fields, was obtained. BAL fluid from the first lavage
was frozen and maintained at −80°C for later cytokine/
chemokine protein analysis.
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Preceding removal of the lungs, the chest cavity was
opened and blood collected by cardiac puncture. The
blood was left at room temperature for 30 min to facilitate
coagulation before centrifugation and separation of serum
for storage at −80°C for future analysis. OVA-specific IgE
was quantified using a modified protocol of the ELISA
MAX mouse IgE kit (Biolegend, San Diego, California,
USA). The kit protocol was followed with the following
exceptions: wells used to measure OVA-specific IgE from
serum samples were coated with 100 μl of a 20 μg/ml
OVA solution overnight at 4°C in place of the coating
antibody. Serum samples were incubated with an equal
volume of protein G sepharose overnight at 4°C. Following
centrifugation, the supernatants were added to wells
during the sample incubation step.
Preparation of lung cells
The right lung was stored in RNAlater (Ambion, Carlsbad,
California, USA) at −20°C for analysis by real-time PCR. A
single cell suspension of lung cells was obtained from the
left lung of each mouse by first mincing the lung and then
incubating the tissue in 1 ml of serum-free DMEM (Life
Technologies, Carlsbad, California) containing Liberase
TM (100 μg/ml; Roche, Indianapolis, Indiana, USA) com-
bined with collagenase XI (250 μg/ml), hyaluronidase 1a
(1 mg/ml) and DNase I (200 μg/ml, Sigma-Aldrich) for
1 h at 37°C. The reaction was stopped with a 20 mM final
concentration of EDTA [29]. Red blood cells were lysed
following enzymatic digestion.
Flow cytometric analysis
Single cell preparations of BAL and lung cells were
incubated for 4 h in 1 ml of RPMI media containing 1%
penicillin/streptomycin, 10% heat-inactivated fetal bovine
serum (Life Technologies); 0.67 μl/ml GolgiStop from the
Cytofix/Cytoperm Fixation/Permeabilization Kit (BD Bio-
sciences, San Diego, California, USA); 50 ng/ml phorbol
12-myristate 13-acetate (PMA) and 500 ng/ml ionomycin
(Sigma-Aldrich). Surface and intracellular cytokine stain-
ing were performed according to the kit protocol. Cells
were double or triple stained with a combination of
the following antibodies: α-CD4-Pacific Blue, α-γδ
TCR-Fluorescein Isothiocyanate (GL3 clone), α-IL-17-
AlexaFluor 647, α-CD3-Pacific Blue (BD Biosciences)
or α-Vγ4-Fluorescein Isothiocyanate (UC3-10A6 clone)
(Biolegend). Stained cells were processed using an LSRII
flow cytometer (BD Biosciences) and analyzed using
FlowJo software (Tree Star, Inc., Ashland, Oregon, USA).
RNA purification & real time PCR analysis
Lung tissue was homogenized and total RNA isolated
following the PureLink RNA Mini Kit (Ambion) protocol.
RNA was reverse-transcribed into cDNA using Oligo dTprimers and SuperScript II (Life Technologies). Real-time
quantitative PCR amplification was performed with Power
SYBR Green (Applied Biosystems, Warrington, UK) using
the Applied Biosystems PCR system. Cycle threshold
values were first normalized to Gapdh gene expression
before quantification by the comparative threshold cycle
method to obtain the gene expression levels from lungs of
OVA sensitized and challenged mouse groups, relative to
the saline control group [30].
Quantitative analysis of BAL fluid mediators
BAL fluid cytokine and chemokine levels were quantified
with the Q-View Imager using the 16-plex mouse cyto-
kine screen (Quansys Biosciences, Logan, Utah, USA).
IL-13 levels in the BAL fluid were quantified using
the ELISA Ready-SET-Go kit (ebioscience, San Diego,
California, USA).
Statistical analysis
Data are expressed as the mean +SEM. Multiple compari-
sons (i.e. antigen- and adjuvant-dependent effects) were an-
alyzed by two-way ANOVA, followed by the Holm-Sidak
post hoc test. Single comparisons (between the 3 OVA-
sensitized groups) were analyzed by one-way ANOVA,
followed by the Holm-Sidak post hoc test. Single com-
parisons (between the 2 antibody treated groups) were
analyzed by an unpaired, two-tailed t-test. p-values less
than 0.05 were considered statistically significant. Figures
and statistics were analyzed using GraphPad Prism 6
(La Jolla, California, USA).
Results
Enhanced airway inflammation, but lack of AHR, in mice
sensitized to OVA in the presence of CFA
In order to establish a mixed model of allergic asthma in
which the IL-17 response could be assessed within an
in vivo Th2 environment, we intraperitoneally (IP) sensi-
tized mice with OVA in the absence (OVA/sal group) or
presence of the adjuvants, alum (OVA/alum group) or
CFA (OVA/CFA group). We confirmed induction of
several classic features associated with allergic airways
disease and differentiated OVA-specific (§) from adjuvant-
specific (*) effects (Figure 1). OVA-IgE was selectively
detected in all OVA sensitized and challenged mice and
was present at significantly higher levels in OVA/CFA
mice (Figure 1A). Total cells, eosinophils, neutrophils and
lymphocytes were significantly increased in the BAL fluid
of OVA/CFA sensitized mice (solid bar) compared to the
CFA control (striped bar). In contrast, inflammation was
not significantly changed in OVA/sal mice and only eosin-
ophils were significantly increased in OVA/alum sensitized
mice (Figure 1B). Moreover, following OVA challenge,
OVA/CFA mice had significantly more macrophages,
eosinophils, neutrophils and lymphocytes, resulting in 3
Figure 1 Serum OVA-specific IgE and airway inflammatory responses are enhanced in OVA/CFA sensitized mice. BALB/c mice were
IP OVA sensitized without adjuvant (OVA/sal), or in the presence of alum (OVA/alum) or CFA (OVA/CFA). Corresponding control groups were
injected with saline, alum or CFA. (A) Serum OVA-IgE levels. OVA-IgE was undetectable in control mice. Mean (+SEM) from 8–12 mice per group
from a minimum of 3 independent experiments. One-way ANOVA, Holm-Sidak. (B) BAL fluid differential cell counts from OVA sensitized groups
(solid bars) and their respective adjuvant controls (striped bars). Mean total cells, macrophages, eosinophils, neutrophils and lymphocytes (+SEM)
are shown for 11–16 total mice from at least 3 independent experiments. Two-way ANOVA, Holm-Sidak. (C) Relative expression of CCL2, CCL11,
CCL24, CXCL1 and CXCL5 in the lung following OVA challenge assessed by real-time PCR. Expression is presented as fold increase relative to the
saline control. Results represent the means (+SEM) from 5–6 total mice per group from a minimum of 2 independent experiments. Two-way
ANOVA, Holm-Sidak. (A-C) §p < 0.05 OVA sensitized groups vs. respective controls (antigen-dependent effects), *p < 0.05 comparisons between
OVA groups (adjuvant-dependent effects).
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alum and OVA/sal mice, respectively. With regard to BAL
fluid cell frequencies, eosinophils were increased in all
OVA-sensitized mice compared to their respective con-
trols, primarily at the expense of macrophages (Additional
file 1: Figure S1). OVA/alum sensitized and challenged
mice had greater frequencies of BAL fluid eosinophils
than OVA/sal mice, while OVA/CFA mice had greater
frequencies of eosinophils, as well as lower frequencies
of both macrophages and lymphocytes compared to
OVA/sal. Regardless of adjuvant, a mixed eosinophilic/
neutrophilic inflammatory profile was observed in all OVA
sensitized groups following OVA challenge.
To assess possible mechanisms by which inflammatory
cell recruitment differed, differences in lung chemokine
expression were assessed following OVA challenge. Levelsof mRNA encoding the macrophage chemoattractant,
CCL2 (MCP-1), the eosinophil chemoattractants CCL11
(eotaxin-1) and CCL24 (eotaxin-2), and the neutrophil
chemoattractant, CXCL1, were increased in OVA/CFA
sensitized mice compared to OVA/sal and/or OVA/alum
sensitized mice with these differences reaching statistical
significance for CCL2, CCL11, and CXCL1 (Figure 1C).
Consistent with the overall increase in BAL fluid inflam-
matory cell influx, mRNA levels for several chemokines
were greater in OVA/CFA mice compared to OVA/sal
and/or OVA/alum mice. Moreover, OVA/CFA mice were
also the only group to show any significant OVA-specific
increases in chemokine expression, with the exception of
the neutrophil chemoattractant, CXCL5.
Following OVA challenge, airway resistance (Figure 2A)
and elastance (Figure 2B) were significantly increased in
Figure 2 AHR is absent in OVA/CFA sensitized mice and Th1/Th2 BAL fluid cytokine levels are influenced by the adjuvant used during
OVA sensitization. Total lung resistance and elastance were assessed 24 h after the last airway OVA challenge. Mean (±SEM) respiratory system
(A) resistance and (B) elastance to increasing concentrations of methacholine (left panels) for the 3 OVA-sensitized mouse groups, as well as at
the 50 mg/ml concentration (right panels) for all 6 groups. Control groups were removed from left panel figures for clarity. Data from 8–14 total
mice per group from 2 independent experiments. (C) Mean BAL fluid levels (+SEM) of IL-4, IL-5, IL-13 & IL-17 were assessed from 7–12 total mice
per group, from at least 2 independent experiments. (A-C) Two-way ANOVA, Holm-Sidak. §p < 0.05 OVA sensitized groups versus respective
controls (antigen-dependent effects); *p < 0.05 comparisons within the OVA sensitized groups (adjuvant-dependent effects), specifically #p < 0.05
OVA/alum vs. OVA/CFA, %p < 0.05 OVA/alum vs. OVA/sal.
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across multiple concentrations of methacholine (left panels),
and to OVA/sal mice at the highest dose (right panels).
Moreover, the OVA-dependent increases (§) in airway re-
sistance and elastance that were observed in OVA/alum
(and OVA/sal) sensitized mice were completely absent in
OVA/CFA sensitized mice. Thus, although OVA-IgE and
airway inflammation were significantly enhanced in OVA/
CFA sensitized mice (Figure 1A, B), AHR was absent. Al-
though adjuvant-only controls showed subtle differences
in respiratory resistance and elastance at the 50 mg/ml
methacholine dose (Figure 2A and B, right panels), these
differences were not statistically different. BAL fluid
was analyzed for Th1, Th2 and Th17 related cytokines.
Levels of IFN-γ were generally low in all groups (data not
shown). In OVA/sal sensitized mice, OVA challenge in-
creased levels of IL-5 and IL-17 (Figure 2C). OVA/alum
sensitized mice had increased IL-4, IL-5, IL-13 and IL-17
levels compared to alum-sensitized mice, post airway chal-
lenge. OVA/alum mice also had significantly greater levels
of these cytokines compared OVA/sal and/or OVA/CFA
mice. Interestingly, OVA/CFA sensitized mice showed no
differences in cytokine levels compared to CFA-sensitized
mice.
When emulsified with OVA at sensitization, CFA increases
IL-17-γδ T cell numbers in the BAL fluid
Following OVA challenge, IL-17 expressing cells were
present in the BAL fluid of all mice, regardless of the
conditions of OVA sensitization (Figure 3A). Although
there was a trend toward a reduced frequency of IL-17+
cells in mice sensitized with OVA/CFA, this difference
did not reach statistical significance (Figure 3B). Neverthe-
less, when taking into account the overall inflammatory
cell influx into the BAL fluid, OVA/CFA sensitized
mice had larger numbers of IL-17+ cells compared to the
other OVA sensitized groups, though this difference was
only significant when compared to the OVA/sal group
(Figure 3C). No antigen-dependent differences were
observed in the OVA sensitized mouse groups compared
to their respective controls.
Several cell types, including Th17 cells [24,31], γδ T
cells [27,28] and alveolar macrophages [32] have been
identified as sources of IL-17 in murine models of allergic
airways disease. Following OVA challenge, we identified
the major IL-17 producing cell(s) in both the BAL and
lungs of OVA/sal, OVA/alum and OVA/CFA sensitized
mice. After gating on IL-17+ cells, the major sources of
IL-17 were identified as CD4+ (Th17) and γδ (IL-17-γδ) T
cells, though the ratio differed depending on the condi-
tions of OVA sensitization (Figure 4A). The ratio of the
frequency of IL-17-γδ to Th17 cells in the BAL fluid
established that Th17 cells were the major source of IL-17
in OVA/sal sensitized mice; that Th17 and IL-17-γδ Tcells contributed almost equally to IL-17 production in
OVA/alum sensitized mice; and that IL-17-γδ T cells were
the main producers of IL-17 in OVA/CFA sensitized mice
(Figure 4B). Similar total numbers of Th17 cells were
present in the BAL fluid of all OVA sensitized and
challenged mice (Figure 4C), but greater numbers of
total IL-17-γδ T cells were recovered from OVA/CFA
sensitized mice compared to OVA/alum and OVA/sal
mice. Only the OVA/alum group had significantly
greater numbers of Th17 cells compared to its respective
control (Figure 4C, left panel), whereas antigen-dependent
differences were absent for total IL-17-γδ Tcells (Figure 4C,
right panel). The ratios of total IL-17-γδ to Th17 cells for
all OVA sensitized mouse groups were similar to the ratios
of the frequencies of the same cells (Figure 4D), with
OVA/CFA sensitized mice having a significantly larger
ratio to both OVA/sal and OVA/alum mice. The median
fluorescence intensity (MFI) of IL-17 was greater in IL-17-
γδ T cells compared to Th17 cells from the BAL fluid
(Additional file 1: Figure S2A, B) for all OVA sensitized
groups, indicating that, while the frequencies of cell types
expressing IL-17 were modified by the type of adjuvant
present at sensitization, the amount of IL-17 expressed by
these individual cells was not affected.
Activating IL-17-γδ T cells leads to inhibition of airway
eosinophilia and AHR
To examine the impact of elevated numbers of IL-17-γδ
T cells present in mice sensitized with OVA/CFA, these
mice were treated with a γδ TCR antibody, UC7-13D5.
Consistent with a study demonstrating that this antibody
activates γδ T cells in vitro and in vivo [33], UC7-13D5
treated OVA/CFA sensitized mice exhibited increased
frequencies of BAL fluid IL-17-γδ T cells (Figure 5A, B
left panel) and, interestingly, IL-17+ cells (Figure 5A, C
left panel), post airway challenge. There was also a posi-
tive trend for the number of IL-17-γδ T cells and IL-17+
T cells to be increased in UC7-13D5-treated mice (right
panels of Figure 5B and C). The majority of the IL-
17-γδ T cells in the UC7-13D5-treated mice were of the
Vγ4 subset (Additional file 1: Figure S3A, B), which has
previously been shown to inhibit AHR and airway
inflammation in murine models of asthma [28]. In
agreement, BAL fluid eosinophils (Figure 6A, B) were
significantly decreased in antibody treated mice compared
to recipients of isotype control antibodies. Moreover,
the frequency of BAL fluid neutrophils was also in-
creased (Figure 6B), which may reflect the increase in
total IL-17 expressing cells in mice treated with the
UC7-13D5 antibody. Finally, both respiratory resistance
and elastance were diminished in OVA/CFA mice
treated with the UC7-13D5 antibody, again consistent
with a negative regulatory role for IL-17-γδ T cells
(Figure 6C).
Figure 3 IL-17 expressing cells are present in the BAL fluid of all OVA sensitized and challenged mice. Cells were stimulated with PMA/
ionomycin and stained to detect IL-17. (A) Representative flow cytometry plots are shown. (B) The frequencies of IL-17 expressing cells for the
OVA groups are shown. One-way ANOVA, Holm-Sidak. (C) The total number of IL-17 expressing cells are shown for OVA groups. Two-way ANOVA,
Holm-Sidak. Mean values (+SEM) from 7–11 total mice per group, from 2 independent experiments. (B-C) *p < 0.05 comparisons between
OVA groups.
Nakada et al. Respiratory Research 2014, 15:90 Page 7 of 14
http://respiratory-research.com/content/15/1/90Discussion
In rodent models of allergic airways disease, the types of
antigen and adjuvant, as well as their concentration,
route and timing of delivery can impact the nature of
the ensuing immune response. Historically, the most
widely used murine models of allergic asthma and rhinitis
have relied upon IP injections of OVA adsorbed to an
aluminum-based adjuvant [34,35]. This class of adjuvant
has been used extensively in animal models of allergic air-
ways disease for its ability to induce a Th2-biased immune
response [20,36]. In contrast, CFA has been recognized
as a Th17-promoting adjuvant and is comprised of a
light mineral oil, a surfactant agent, and heat-killed
Mycobacterium tuberculosis (Mtb) that creates an emul-
sion when mixed with an aqueous solution [37]. A great
deal of our understanding of the IL-17/CFA relationship
has come from experimental autoimmune encephalomy-
elitis models of multiple sclerosis [38]. Nevertheless,
antigen sensitization with CFA has rarely been used
in models of allergic airways disease. Our goal was to as-
sess how the choice of adjuvant—alum or CFA—affected
Th2 and Th17 type inflammatory responses in the airways
post antigen challenge.CFA has been widely used in experimental studies for
its unsurpassed ability to enhance antibody production
against a number of different antigens [37]. This was
confirmed in our analysis as OVA/CFA sensitized mice,
post airway challenge, had significantly greater levels of
serum OVA IgE compared to both OVA/sal and OVA/
alum sensitized mice. Abundant data demonstrate that,
independent of the mouse strain, mice IP sensitized with
OVA/alum have robust airway eosinophilia post chal-
lenge [34,35]. Nevertheless, the airways of C57Bl/6 mice
sensitized IP with OVA/alum or OVA/CFA can also
exhibit a mixed eosinophilic/neutrophilic inflammatory
profile of similar magnitude following acute antigen chal-
lenge [22]. Our data indicate that Balb/c mice IP sensi-
tized to OVA with alum or CFA yield mixed eosinophilic/
neutrophilic inflammatory profiles where equal ratios of
both cell types were recovered in the BAL fluid. These
data suggest that both Th2 and IL-17 responses, which are
associated with airway eosinophilia [39] and neutrophilia
[21], respectively, may be induced with either adju-
vant. Although AHR is often correlated with airway
inflammation, there is evidence from humans [40,41],
as well as murine models [42,43], that AHR can occur
Figure 4 OVA/CFA sensitized mice have more γδ+IL-17+ T cells in the BAL fluid. BAL fluid cells were stimulated with PMA/ionomycin and
triple stained with α-CD4, α-γδ TCR and α-IL-17 antibodies. (A) Representative flow cytometry plots of cells in BAL fluid (top panel) and lung
(bottom panel) gated first to identify IL-17+ cells and subsequently to identify frequencies of CD4 and γδ T cells. (B) The frequency distribution of
IL-17+ cells within the CD4 and γδ T cell populations is presented as the ratio (γδ/CD4) of these cells. One-way ANOVA, Holm-Sidak. (C) Total
numbers of CD4+IL-17+ and γδ+IL-17+ populations calculated from the frequency of these cells and the total cell counts are shown. Two-way
ANOVA, Holm-Sidak. (D) The distribution of total γδ+IL-17+ and CD4+IL-17+ T cells is presented as the ratio (γδ/CD4) of these cells. One-way ANOVA,
Holm Sidak. (B-D) Data are from 7–11 total mice per group from at least 2 independent experiments. *p < 0.05 comparisons between OVA groups
(adjuvant-dependent effects), §p < 0.05 OVA sensitized groups versus respective controls (antigen-dependent effects).
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mice sensitized with OVA/CFA had significantly more
inflammation following OVA challenge, as assessed from
the BAL fluid. Nevertheless, both antigen- and adjuvant-
specific increases in airways resistance and elastance were
completely absent in these mice. Comparatively, OVA/
alum sensitized mice exhibiting moderate inflammation,
had both antigen- and adjuvant-dependent increases in
AHR. These differences in airways resistance and elas-
tance may be related to BAL fluid levels of IL-4 and IL-13,
which were elevated in only the OVA/alum sensitized
mice. Intratracheal instillations of IL-13 to naïve mice [44]or IL-4 to IL-13 deficient mice can induce AHR [21].
Interestingly, the same studies showed IL-4 and IL-13 to
be potent inducers of airway eosinophilia, whereas in our
study, airway hyporesponsive, highly eosinophilic OVA/
CFA sensitized mice had comparatively lower BAL fluid
levels of both cytokines. We therefore considered other
mediators to provide a possible explanation for the dis-
connect between AHR and inflammation observed in
OVA/CFA mice. The ability of IL-17 to act as both a posi-
tive and negative regulator of asthma [27], as well as the
ability of CFA to induce IL-17 in models of experimental
autoimmune encephalomyelitis [45] made this particular
Figure 5 (See legend on next page.)
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Figure 5 Frequencies of total IL-17 expressing cells and of IL-17-γδ cells are increased in OVA/CFA sensitized mice treated with a γδ
TCR stimulatory antibody. OVA/CFA sensitized mice were IV injected with a γδ TCR stimulatory antibody (UC7-13D5) or isotype control before
airway challenge. BAL fluid cells were stimulated with PMA/ionomycin and stained with α-γδ TCR and α-IL-17 antibodies. (A) Representative flow
cytometry plots of BAL fluid cells. The mean frequencies (left panels) and numbers (right panels) of (B) IL-17-γδ and (C) IL-17+ BAL fluid cells are
presented for 5 total mice per group from 2 independent experiments. (B-C) Unpaired, two-tailed t-test. *p < 0.05.
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induce AHR in mice, under some circumstances it can
promote Th2-dependent AHR and inflammation [26].
We identified the cellular source(s) of IL-17 in mice
sensitized under different adjuvant conditions. Following
OVA challenge, IL-17 was expressed predominantly by a
combination of CD4+ and γδ T cells in the BAL fluid
and lungs (Figure 4A) of all OVA-sensitized and chal-
lenged mice. However, in OVA/sal sensitized mice, IL-17
was produced primarily by CD4+ T cells. Alum or CFA,
given at the time of sensitization, affected this distribu-
tion by skewing IL-17 expression toward γδ T cells. Mtb,
an essential component of CFA, preferentially induces
IL-17 expression from γδ T cells rather than CD4+ T cells
through activation of the Nalp3 inflammasome [45,46].
Moderate skewing of IL-17 production toward γδ T cells
also occurred in mice sensitized with OVA/alum. This
may reflect the ability of alum to activate the Nalp3
inflammasome [35,47], albeit less potently than CFA, or
depend on the quantity of alum used at sensitization.
Our data demonstrating that IL-17-γδ T cells, Th17
cells (Figure 4C) and total IL-17+ cells (Figure 3C) recov-
ered in the BAL fluid did not necessarily coincide with
BAL fluid levels of IL-17 (Figure 2C), are consistent with
data from other groups [24,28]. For example, IL-17 levels
in the BAL fluid of both airway and IP sensitized mice
were undetectable at a time point when total Th17 cells,
assessed by flow cytometry, were significantly higher in
airway sensitized mice [24]. Thus, apparent differences in
IL-17 cytokine levels relative to IL-17 expressing cells may
simply reflect the timing of assessment, as the ability to
detect IL-17 in the BAL fluid may be quite transient
[24,28], whereas detection of cells with the potential to
produce IL-17 may be more stable/longlasting.
In murine models of allergic asthma, IL-17 expression
is most often associated with CD4+ T cells, although γδ T
cells and macrophages can also express IL-17 [24,28,32].
Several factors, including the quantity of cytokine pro-
duced, as well as the timing and location and cell source,
likely impact the outcome of IL-17 production. For ex-
ample, while Th17 cells appear to promote Th2 responses,
such as eosinophil recruitment to the airways, we and
others have shown that IL-17-γδ T cells actually inhibit
Th2-associated AHR and/or inflammation [27]. Murdoch
et al. specifically showed that 64% of IL-17-γδ T cells were
of the Vγ4+ subset [28]. This specific subset of γδ T cells
actively suppresses AHR [48] and may accomplish thiswithout affecting inflammation [49]. We similarly showed
a population of IL-17+Vγ4+ cells constituting a large ma-
jority of the IL-17-γδ T cells in the BAL fluid of OVA/
CFA sensitized mice (Additional file 1: Figure S3). Thus,
the prominent IL-17-γδ T cell population recovered in
OVA/CFA sensitized mice may explain, at least in part,
the absence of AHR, despite the robust inflammatory
response. For these same reasons, regulatory T cells
are not likely to be involved in the suppression of
AHR, due to their well-established role in suppressing
inflammation [50].
In order to better understand how IL-17-γδ T cells
regulated airway inflammatory responses in OVA/CFA
sensitized mice, we treated these mice with a γδ TCR
stimulatory antibody (UC7-13D5), the outcome of which
was a substantial increase in the frequency of IL-17-γδ
T cells accompanied by reductions in both AHR and
eosinophil influx. We were not surprised to find that the
increase in IL-17-γδ T cells corresponded to a decrease
in AHR, in particular since the majority of the IL-17-γδ
T cells induced in OVA/CFA sensitized mice appeared
to be the Vγ4, inhibitory subset. Unlike the inhibition of
AHR, the reduced number of airway eosinophils in
UC7-13D5 treated mice was unexpected as OVA/CFA
sensitized mice that followed the 4 week sensitization
and challenge protocol had increased IL-17-γδ T cells
in the BAL fluid (Figure 4C) and suppressed AHR
(Figure 2A, B), but had highly inflamed airways, includ-
ing abundant eosinophils (Figure 1B). γδ T cells (IL-17+
and Vγ4+) are described as having either an inhibitory
or no effect on airway eosinophilia, based on different
OVA models of allergic airways disease [28,48,49]. Careful
examination of the literature indicates that this may be a
temporal issue. In these OVA models, γδ T cells are con-
sistently elevated in numbers at the peak of eosinophil
recruitment (24–48 hours after the last airway challenge),
suggesting that IL-17-γδ T cells do not have an immediate
inhibitory effect on the influx of eosinophils. However, in
the days following antigen challenge, (i.e. recovery phase),
IL-17-γδ T cells have specifically been shown to decrease
airway eosinophil numbers and further attenuate AHR
[28]. Where γδ T cells are reported as having no effect on
eosinophil recruitment, measurements were taken at the
peak of inflammation and compared to mice that received
a Vγ4 neutralizing antibody [49], which would neutralize a
population of cells that has yet to influence airway eosino-
phil numbers. In contrast, in our studies, the UC7-13D5
Figure 6 (See legend on next page.)
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Figure 6 OVA/CFA sensitized mice receiving a γδ TCR stimulatory antibody, have reduced airway eosinophilia and AHR. OVA/CFA
sensitized mice were IV injected with a γδ TCR (UC7-13D5) stimulatory antibody or isotype control before airway challenge. The mean (A) total
cell counts and (B) frequencies of macrophages, eosinophils, neutrophils and lymphocytes (+SEM) are shown for 5 total mice per group from 2
independent experiments. (C) Total lung resistance and elastance were assessed 24 h after the last airway OVA challenge. Mean (±SEM)
respiratory system resistance and elastance to increasing concentrations of methacholine are shown. (A-C) Unpaired, two-tailed t-test. *p < 0.05,
ns = not significant.
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tized mice, stimulated and thus activated the γδ T cells,
which may have allowed them to reduce airway eosinophil
numbers even at 24 hours after the last airway challenge.
Further studies are required to confirm these findings.
IL-17-γδ T cells have been reported to increase IL-17
production from Th17 and other cell types [38,51,52].
This may explain the increase in total IL-17+ cells recov-
ered in the BAL fluid of mice treated with the UC7-13D5
antibody. Consistent with the literature, the frequen-
cies of neutrophils in UC7-13D5 treated mice (Figure 6B)
reflected the increase in IL-17+ cells (Figure 5C) [24,53].
However, the overall neutrophil cell count remained low
and did not differ between UC7-13D5 and isotype control
antibody treated OVA/CFA sensitized mice (Figure 6A).
The UC7-13D5 γδ TCR antibody has previously been
used to functionally deplete γδ Tcells in vivo [54]. Though
we used comparable concentrations of this antibody,
as discussed above, our data indicate that the target
cells were neither neutralized, nor functionally depleted.
In fact, our data are consistent with data provided by
Koenecke, et al. demonstrating that γδ T cells are acti-
vated by UC7-13D5 [33]. To study γδ T cells in OVA/CFA
sensitized mice, two different antibodies were used:
mice were injected with the UC7-13D5 γδ TCR anti-
body, followed by γδ T cell detection by flow cytome-
try using the GL3 γδ TCR antibody. While the treatment
and staining antibodies differ, our data and others [33]
suggest that the GL3 and UC7-13D5 antibodies compete
for the same γδ TCR epitope, as the γδ MFI was lower,
but not to the extent of depletion, in BAL fluid cells recov-
ered from UC7-13D5 antibody compared to control anti-
body treated mice (Figure 5). This was also the case for
the Vγ4 staining antibody (UC3-10A6 clone), but ap-
peared to compete to a lesser degree with the UC7-13D5
antibody (Additional file 1: Figure S3). In either case, it is
clear that the γδ T cells were not depleted. Furthermore,
as discussed above, there was a significant increase in the
expression of IL-17 within the γδ T cells from UC7-13D5
treated mice, while the frequency of total γδ T cells was
unchanged compared to that in mice treated with the
isotype control (data not shown).
Although the adjuvants, alum and CFA, significantly
impacted the distribution of IL-17 expression between
the CD4+ and γδ T cell populations, the median fluores-
cence intensity (MFI) of IL-17 within each cell type wasunaffected. In fact, the MFI of IL-17 in BAL fluid γδ T
cells was significantly greater than in CD4+ T cells for all
three OVA sensitized groups. Lockhart et al. discussed
the frequency of IL-17 expression within the same cell
populations in a murine model of Mtb infection [46].
Although they did not directly address the MFI of IL-17,
it too appeared to be higher in γδ T cells than in CD4+ T
cells. Therefore, the level of expression of IL-17 in this
model, as well as in our model of allergic airways disease,
may be applicable to other physiological or pathological
lung conditions. We previously demonstrated that a low
dose of IL-17 augments IL-13-induced airway inflamma-
tory responses, while a higher dose of IL-17 attenu-
ates these responses [27]. In parallel, the “low dose”
of IL-17 produced by CD4+ T cells in the current
study may have augmented disease while our data
suggest that the “high dose” of IL-17 produced by γδ T
cells attenuated disease.
Conclusions
Altogether, our data demonstrate that intraperitoneal
OVA sensitization with and without the adjuvants, alum
and CFA, regulated the profile of IL-17 producing cells
localized to the lung post OVA challenge, providing
insight into potential mechanisms by which IL-17 may
negatively regulate allergic airways disease. Notwith-
standing the large influx of inflammatory cells to the
airways, AHR was completely absent in OVA/CFA
sensitized mice post OVA challenge. This lack of AHR
coincided with an increase in IL-17-γδ T cells in the BAL
fluid, in line with previous data demonstrating that these
cells are potent inhibitors of airway inflammatory re-
sponses [27,28]. While the dual role of IL-17 makes it
a complex target for drug development, our data sug-
gest that treatments specifically focused on enhancing
the IL-17-γδ T cell population may be beneficial for
asthmatics.
Additional file
Additional file 1: Figure S1. Frequencies of macrophages, eosinophils,
neutrophils and lymphocytes in the BAL fluid of OVA sensitized mice
and their respective controls. 11–16 mice from at least 3 independent
experiments. Two-way ANOVA, Holm-Sidak. §p < 0.05 OVA groups vs.
their respective controls; *p < 0.05 versus OVA/sal, ^p < 0.05 versus
CFA. Additional relevant comparisons were not significantly different.
Figure S2. Frequencies of IL-17+ cells within the γδ T cell population and
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http://respiratory-research.com/content/15/1/90the MFI of IL-17 are greater than those of CD4+ T cells from the
BAL fluid. Cells were triple stained with α-CD4, α-γδ TCR and α-IL-17
antibodies. (A) Representative flow cytometry plots of BAL fluid cells
from OVA sensitized groups. (Δ) indicates the MFI of IL-17 within the
IL-17-expressing CD4+ and γδ TCR+ cell populations on a log scale. (B)
The MFI of IL-17 expression within the IL-17 expressing CD4+ and γδ T
cell populations are shown. Flow cytometry plots and mean values
(+SEM) are from 7–9 mice per group from at least 2 independent
experiments. Two-way ANOVA, Holm-Sidak. *p < 0.05. Figure S3. The
majority of IL-17-γδ T cells in the BAL fluid of OVA/CFA sensitized mice
are of the Vγ4 subset and increase in frequency with activation by the γδ
TCR antibody. OVA/CFA sensitized mice were IV injected with a γδ TCR
(UC7-13D5) stimulatory antibody or isotype control before airway OVA
challenge. BAL fluid cells were double stained with α-IL-17 and either the
α-γδ TCR or α-Vγ4 antibodies. Representative flow cytometry plots of the
frequencies of γδ+IL-17+ and Vγ4+IL-17+ cells from recipients of (A)
control or (B) UC7-13D5 antibody are shown within the total live BAL
fluid cell population and are representative of 2–3 mice per group.
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